SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Factory plant conveyor line production development industrial interior design flat background concept illustration
Manufacturing
Novo-Catalent Deal Represents ‘Defining Moment’ for CDMO Sector
Novo Holdings’ acquisition of Catalent has ignited concerns from industry stakeholders, who fear that the consolidation could limit competition, but there is also the possibility that the deal could represent an opportunity for smaller-scale CDMOs to find new partners.
November 13, 2024
 · 
4 min read
 · 
Ben Hargreaves
U.S. Capitol surrounded by money and pill bottles/Taylor Tieden for BioSpace
Opinion
Don’t Import Bad Policy Ideas on Drug Pricing
Suggestions that the U.S. should emulate other countries on drug price controls or patents obscure how our present policies have allowed drug development to flourish.
November 13, 2024
 · 
4 min read
 · 
Kirsten Axelsen
Facade of AstraZeneca's office in Shanghai, China
Earnings
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the “important” U.S. market.
November 12, 2024
 · 
3 min read
 · 
Kate Goodwin
Pictured: Bayer's office in Berlin, Germany/iStock
Earnings
Bayer Earnings ‘Not Pretty,’ CEO Bill Anderson Admits As He Urges Calm
Bayer reported a decline of 37% in earnings per share on Tuesday, which sent its stock down 12%. CEO Bill Anderson urged investors to be patient as the company executes on a performance-boosting strategy outlined in March.
November 12, 2024
 · 
2 min read
 · 
Annalee Armstrong
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Earnings
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
November 12, 2024
 · 
9 min read
 · 
Annalee Armstrong
Roche's tower in Shanghai, China
Deals
Roche Inks Potential $1.8B Deal With Flare to Target Transcription Factors in Cancer
With $70 million upfront and more than $1.8 billion on the line, Roche will gain access to Flare’s drug discovery engine to bolster its oncology pipeline.
November 12, 2024
 · 
2 min read
 · 
Tristan Manalac
vector 3d lungs made of triangular polygons on a blue background
Clinical research
Insilico Aces Second Mid-Stage IPF Trial in a Row
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and was well-tolerated across all dosing groups.
November 12, 2024
 · 
2 min read
 · 
Heather McKenzie
June 10, 2020 Sunnyvale / CA / USA - The new 23andme headquarters in Silicon Valley; Based on a saliva sample, 23andMe provides reports about the customer's health, traits and ancestry
Layoffs
23andMe Cuts Headcount by 40%, Drops Drug Discovery Work
In line with the restructuring initiative, 23andMe is looking for strategic opportunities for its pipeline assets, including licensing deals or outright sales.
November 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Gene therapy
Neurogene Shares Tank After Adverse Event Linked to Early-Stage Rett Syndrome Gene Therapy
Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated at a lower dose and showed promising efficacy outcomes.
November 12, 2024
 · 
3 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS